Levonorgestrel 52 mg intrauterine device placement without uterine sounding: A feasibility study.

Objectives: To evaluate feasibility of levonorgestrel 52 mg intrauterine device (IUD) placement without uterine sounding.

Study Design: We performed a three-phase feasibility study from February 2023-May 2024. In phase one, participants had levonorgestrel 52 mg IUD placement with sounding.

Comparative efficacy of combined oral contraceptives and the levonorgestrel 52 mg IUD.

The relative risk of pregnancy with the levonorgestrel 52 mg IUD is 3 times lower than with optimal combined oral contraceptive use.